BC Extra | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb   Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP)...
BC Week In Review | Aug 17, 2018
Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...
BC Week In Review | Jul 20, 2018
Financial News

Aridis proposes $34.5M IPO

Infectious disease company Aridis Pharmaceuticals Inc. (San Jose, Calif.) proposed on July 18 to raise $34.5 million in an IPO on NASDAQ underwritten by Cantor, Maxim Group and Northland Capital Markets. The company's lead candidate...
BC Week In Review | Jun 29, 2018
Clinical News

Arsanis discontinues Phase II of lead anti-infective

Arsanis Inc. (NASDAQ:ASNS) discontinued a double-blind, international Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. In...
BC Extra | Jun 28, 2018
Clinical News

Arsanis discontinues Phase II of lead anti-infective, shares plummet

Arsanis Inc. (NASDAQ:ASNS) discontinued a Phase II trial of lead candidate ASN100 to prevent Staphylococcus aureus pneumonia after a futility analysis showed that the candidate was unlikely to meet its primary endpoint. The company's shares...
BC Innovations | Feb 14, 2018
Translation in Brief

Poring over pain

Harvard Medical School researchers have figured out how to hijack the pores formed by bacterial toxins on nerves to deliver normally membrane-impermeable compounds into the cells and treat pain the pathogens cause. While the January...
BC Extra | Nov 16, 2017
Financial News

Arsanis rises on $60M IPO and private placement

Arsanis Inc. (NASDAQ:ASNS) jumped $4.03 (40%) to $14.03 on its first day of trading Thursday after raising $60 million in an IPO on NASDAQ and a concurrent private placement. The company raised $40 million through...
BC Extra | Apr 26, 2017
Financial News

Gates Foundation leads Arsanis' $45.5M series D

Infectious disease company Arsanis Inc. (Waltham, Mass.) raised $45.5 million in a series D round led by the Bill & Melinda Gates Foundation (Seattle. Wash.), a new investor. Also participating were new investors GV and...
BC Week In Review | Feb 10, 2017
Clinical News

ASN100: Ph II started

Arsanis began a double-blind, placebo-controlled, international Phase II trial to evaluate a single dose of IV ASN100 in about 350 high-risk, mechanically ventilated patients. ASN100 was discovered under a deal with Adimab, which is using...
BC Week In Review | Sep 21, 2015
Clinical News

Salvecin regulatory update

FDA granted Fast Track designation to AR-301 from Aridis to treat hospital-acquired and ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus. The human IgG1 mAb against S. aureus alpha-hemolysin (aHL) generated using Aridis’ MabIgX technology is...
Items per page:
1 - 10 of 10